A first-in-class RNA therapy targeting the liver to simultaneously address fatty liver disease and cardiovascular lipid risk, with a single injection every 3 to 6 months.
Most MASLD/MASH patients don't have "just liver disease." They carry cardiometabolic risk that kills first.
Existing therapies treat one axis. SIG-001 is the only approach designed to simultaneously address MASLD/MASH and atherogenic dyslipidemia.
SIG-001 uses GalNAc-conjugated siRNA, the same validated delivery platform as inclisiran and givosiran, to silence a novel liver-expressed gene with a central role in lipid metabolism.
Pre-clinical work runs through mid-2026, followed by IND-enabling studies through 2027. Phase 1 is planned for 2028–2029, with Phase 2a proof-of-concept anticipated 2030–2031.
A multidisciplinary team combining industry, clinical, scientific, and financial expertise with direct ties to the biology underpinning SIG-001.
Industry experience across Sanofi, AstraZeneca and early-stage start-ups, with consulting at PwC. R&D, CMC and regulatory strategy background spanning first-in-class cardiovascular drugs, fitusiran, mRNA therapeutics, and GalNAc-siRNA.
Internationally recognised authority on a therapeutically relevant enzyme family, the same group that underpinned the development of landmark lipid-lowering medicines now on the multibillion pharma market. 800+ peer-reviewed publications and major national scientific honours.
Previous roles as Chief of Staff, CFO, CTO and Head of M&A following his career at McKinsey. Proven track record in capital allocation and strategic transactions.
20+ years of operational leadership across 250+ client sites. Program management and operational excellence in complex multi-site R&D organisations.
Our in-house scientific team brings hands-on experience in metabolic disease and immuno-oncology from leading European biotech, currently advancing SIG-001 through lead selection.
SIG-001 is supported by world-class scientific expertise across enzyme biology, hepatology, and RNA therapeutics.
Silengenics is building a board of strategic and business advisors spanning biotech investment, regulatory affairs, and commercial development. Full advisory board announcement forthcoming.
Access our full product overview including pipeline, mechanism of action, market opportunity, and financing plan. Available to qualified investors upon request.
Password-protected. Available to qualified and accredited investors only.
We are engaging with qualified investors, clinical collaborators, and potential strategic partners as we advance SIG-001 toward the clinic.
